AMWL at a glance
The past year
Chart+178.7% $11.04, close Nov 18
- From the highest close
- −26.3%
- Vs the 200-day average
- +17.4%
Short interest
History250,235 shares
- Of shares outstanding
- 1.61%
- Since the last report
- +21.1%
- Days to cover
- 1.7 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 13 – Nov 19
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
AMWL price history
Loading recent earnings…
Investment thesis
What must happen next
Healthcare buyers continue to value a dedicated, regulated digital-care platform over generic video tools or bundled EHR offerings, allowing AMWL to defend its installed base rather than becoming a commoditized feature.HoldingMateriality: High
Annual GAAP revenue remained material at $249.3 million in FY2025 despite heavy competitive pressure disclosed in MD&A. If this holds, revenue can stabilize and the turnaround has time; if it breaks, cost cuts cannot offset structural demand loss.
Watch: Epic, Cerner, Allscripts, or athenahealth make virtual-care workflows sufficiently native to the EHR that clients stop buying a separate AMWL platform.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Annual GAAP revenue remained material at $249.3 million in FY2025 despite heavy competitive pressure disclosed in MD&A.
Open source ↗Management’s cost actions and platform focus are improving operating leverage without cutting so deeply that the product becomes uncompetitive.StrengtheningMateriality: High
Annual GAAP operating loss improved from $217.5 million in FY2024 to $105.3 million in FY2025. This determines whether AMWL can become self-funding or must rely on its balance sheet and possible dilution.
Watch: Competitor product advances force AMWL to reaccelerate R&D and sales spending before revenue improves.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Annual GAAP operating loss improved from $217.5 million in FY2024 to $105.3 million in FY2025.
Open source ↗AMWL’s cash balance gives it enough runway to execute the turnaround, but only if cash burn keeps moving down rather than reaccelerating.StrengtheningMateriality: Medium
Cash was $182.3 million at FY2025 year-end. If runway holds, shareholders retain turnaround optionality; if burn reaccelerates, dilution or strategic distress becomes central.
Watch: Regulatory compliance costs rise materially because AMWL must restructure clinical or AMG-related arrangements.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $182.3 million at FY2025 year-end.
Open source ↗Healthcare regulatory complexity remains a barrier that favors specialized digital-care operators, rather than becoming a compliance shock that forces AMWL to alter services or restructure clinical relationships at high cost.HoldingMateriality: Medium
The company’s filing identifies corporate practice of medicine, licensure, online prescribing, privacy, cybersecurity, Stark Law, and Anti-Kickback Statute compliance as central operating requirements. If compliance know-how is an advantage, it helps defend pricing and customer trust; if regulators force changes, revenue and margins can deteriorate quickly.
Watch: Federal or state regulators scrutinize AMWL’s AMG relationship or corporate-practice-of-medicine structure and require costly restructuring.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company’s filing identifies corporate practice of medicine, licensure, online prescribing, privacy, cybersecurity, Stark Law, and Anti-Kickback Statute compliance as.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Healthcare buyers continue to value a dedicated, regulated digital-care platform over generic video tools or bundled EHR offerings, allowing AMWL to defend its installed base rather than becoming a commoditized feature. If this holds, revenue can stabilize and the turnaround has time; if it breaks, cost cuts cannot offset structural demand loss.
Management’s cost actions and platform focus are improving operating leverage without cutting so deeply that the product becomes uncompetitive. This determines whether AMWL can become self-funding or must rely on its balance sheet and possible dilution.
AMWL’s cash balance gives it enough runway to execute the turnaround, but only if cash burn keeps moving down rather than reaccelerating. If runway holds, shareholders retain turnaround optionality; if burn reaccelerates, dilution or strategic distress becomes central.
Healthcare regulatory complexity remains a barrier that favors specialized digital-care operators, rather than becoming a compliance shock that forces AMWL to alter services or restructure clinical relationships at high cost. If compliance know-how is an advantage, it helps defend pricing and customer trust; if regulators force changes, revenue and margins can deteriorate quickly.
All standing thesis claims
Original report summary
large healthcare buyers keep paying for a dedicated digital-care platform while management turns a still-lossmaking revenue base into self-funding cash flow.
Bull case and bear case
Bull case and bear case for American Well
Where the evidence on American Well stands: Holding on the latest evidence (Oct 17, 2026). Of its 4 thesis points, 2 strengthening and 2 holding.
Bull case: what the evidence supports
Healthcare buyers continue to value a dedicated, regulated digital-care platform over generic video tools or bundled EHR offerings, allowing AMWL to defend its installed base rather than becoming a commoditized feature.
Management’s cost actions and platform focus are improving operating leverage without cutting so deeply that the product becomes uncompetitive.
AMWL’s cash balance gives it enough runway to execute the turnaround, but only if cash burn keeps moving down rather than reaccelerating.
Healthcare regulatory complexity remains a barrier that favors specialized digital-care operators, rather than becoming a compliance shock that forces AMWL to alter services or restructure clinical relationships at high cost.
Bear case: what would count against it
Epic, Cerner, Allscripts, or athenahealth make virtual-care workflows sufficiently native to the EHR that clients stop buying a separate AMWL platform.
Competitor product advances force AMWL to reaccelerate R&D and sales spending before revenue improves.
Regulatory compliance costs rise materially because AMWL must restructure clinical or AMG-related arrangements.
Thesis-Break Engine
Thesis-break watch · American Well
No break has crossed American Well’s thesis. Its break conditions are checked against every new filing as it lands.
Early warning
The break condition read on the trailing twelve months through American Well’s latest quarterly report, ahead of the annual figure it is written on.
- Revenue decline, trailing 12 months
Across all companies, this kind of early warning has happened 3,039 times before. Those stocks beat the market by a median of 1% over the next six months, and 32% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
American Well filed an SEC 8-K on 2026-08-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedChanged certifying accountant.
American Well filed an SEC 8-K on 2026-07-21: Changed certifying accountant. It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
American Well filed an SEC 8-K on 2026-07-14: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Epic, Cerner, Allscripts, or athenahealth make virtual-care workflows sufficiently native to the EHR that clients stop buying a separate AMWL platform.
- Competitor product advances force AMWL to reaccelerate R&D and sales spending before revenue improves.
- Regulatory compliance costs rise materially because AMWL must restructure clinical or AMG-related arrangements.
- Federal or state regulators scrutinize AMWL’s AMG relationship or corporate-practice-of-medicine structure and require costly restructuring.
AMWL news
Loading headlines…
Financial statements
AMWL income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
AMWL: quick answers
- When does American Well (AMWL) report earnings next?
- American Well's next results are projected for February 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 3, 2026. Earnings calendar
- What is AMWL's short interest?
- As of October 30, 2026, 250,235 AMWL shares were sold short, 1.61% of its shares outstanding, up 21.1% from the count before. At the stock's average daily volume that is 1.7 days to cover. FINRA publishes the count twice a month. AMWL short interest history

